8-K: Adicet Bio Advances Prula-cel, Secures IND for ADI-212

Adicet Bio announces completion of last patient visit for prula-cel SLE study, with topline data expected September 2026, and provides corporate updates including FDA IND clearance for ADI-212.

Summary

• Adicet Bio has completed the last patient visit for its Phase 1 study of prula-cel (ADI-001) in patients with Systemic Lupus Erythematosus (SLE) with or without Lupus Nephritis (LN).
• Topline data from this planned analysis of prula-cel is expected in September 2026.
• The company received FDA clearance for its Investigational New Drug (IND) application for ADI-212, a gene-edited cell therapy candidate for metastatic castration-resistant prostate cancer (mCRPC).
• Adicet Bio plans to initiate enrollment for the ADI-212 Phase 1 clinical study in mCRPC patients in the fourth quarter of 2026.
• The company is also progressing its next-generation in vivo CAR-T platform, with the first candidate expected to enter clinical development in the second half of 2027.
• A clinical update for prula-cel in patients with systemic sclerosis is anticipated in the fourth quarter of 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, highlighting progress in clinical trials and regulatory milestones, though key data readouts are still anticipated.

Positives

• Completion of the last patient visit for the prula-cel SLE study, moving closer to data readout.
• FDA clearance of the IND for ADI-212, enabling the initiation of a Phase 1 clinical study in mCRPC.
• Advancement of the in vivo CAR-T platform with a first candidate expected in clinical development by 2H 2027.
• Expansion of prula-cel administration into the outpatient setting, improving patient access and convenience.
• The company expects to host an investor webcast upon release of the prula-cel topline data.

Negatives

• Topline data for the prula-cel SLE study is still pending and expected in September 2026.
• The first candidate from the in vivo CAR-T portfolio is not expected to enter clinical development until the second half of 2027.
• While IND is cleared for ADI-212, patient enrollment for the Phase 1 study is not expected to begin until Q4 2026.

Risks

• Clinical studies may fail to demonstrate adequate safety and efficacy of product candidates, which could prevent, delay, or limit regulatory approval and commercialization.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• The production and product release processes necessary for commercialization are similarly lengthy, time-consuming, and unpredictable.
• Global economic conditions and public health emergencies could disrupt preclinical and clinical studies, business operations, and the ability to raise capital.
• Positive interim results from a clinical study may not be predictive of future or ongoing study results.

Future Outlook

Topline data from the prula-cel study in SLE patients is expected in September 2026. The company plans to initiate enrollment for the ADI-212 Phase 1 study in Q4 2026. The first candidate from the in vivo CAR-T portfolio is anticipated to enter clinical development in the second half of 2027. A clinical update for prula-cel in systemic sclerosis is expected in Q4 2026.

Management Comments

• "We are pleased with the level of interest from investigators and patients in our study evaluating prula-cel in patients with SLE with or without LN and look forward to the planned readout later this month."
• "As we advance this program, we are also executing across our broader pipeline, including initiating start up activities for our Phase 1 study of ADI-212 in mCRPC, following the recent IND clearance by the FDA, while continuing to progress our differentiated in vivo CAR-T platform, with our first candidate expected to enter clinical development in the second half of 2027."

Industry Context

StockSavvy.ai notes that Adicet Bio's progress aligns with the broader trend in the biotechnology sector focusing on advanced cell therapies, including CAR T, for both autoimmune diseases and oncology. The company's dual approach with allogeneic gamma delta CAR T and in vivo CAR T therapies positions it to address diverse therapeutic areas.

Stakeholder Impact

• Shareholders: Potential positive impact from progress in clinical development and regulatory milestones, though key data is still pending.
• Patients: Continued access to investigational therapies for SLE and mCRPC, with potential for improved treatment options.
• Investigators: Continued engagement in clinical trials, contributing to the advancement of novel therapies.

Next Steps

• Release topline data from the prula-cel study in SLE patients (expected September 2026).
• Host an investor webcast upon release of prula-cel topline data.
• Initiate enrollment in the Phase 1 study of ADI-212 in mCRPC patients (expected Q4 2026).
• Provide a clinical update in patients with systemic sclerosis (expected Q4 2026).
• Advance the first candidate from the in vivo CAR-T portfolio into clinical development (expected 2H 2027).

Key Dates

Recommendation

The filing indicates steady progress in clinical development and regulatory milestones, particularly with the IND clearance for ADI-212. However, critical topline data for the prula-cel SLE study is still pending. The company's diversified pipeline is promising, but the timeline for the in vivo CAR-T candidate is extended. Therefore, a 'hold' recommendation is appropriate pending the upcoming data readouts and further clinical progress.

Keywords

prula-cel, ADI-212, CAR T, Systemic Lupus Erythematosus, Lupus Nephritis, metastatic castration-resistant prostate cancer, autoimmune diseases, biotechnology